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Innovations
Affinium Pharmaceuticals, Inc.:
Structure-Guided Drug Discovery
that you can visualize in the target, obtain an accurate image, and, fi-
nally, inspecting and analyzing thou-and then you can start to see where
sands of data sets corresponding toto make modifications.” He adds,
The assessment of function inferred
from structure is the name of the
game in structural proteomics.
There is an abundance of informa- each drop of protein. It is important“Everybody will design drugs this
tion to be acquired from genomic to recognize that data storage ofway in the future.”
and proteomic studies, and there is thousands of images is rather daunt-The founding scientists of Affin-
a lot that is needed. Less than 30% ing. If one image requires 2 MB andium, Aled Edwards, PhD, Cheryl
of all predicted eukaryotic proteins there are 10,000 drops (images), thisArrowsmith, PhD, and Jack Green-
have a known function, leaving an could result in 20 GB of data on ablatt, PhD, have made progress in
abundance of proteins uncharacter- daily basis.the field of structure biology and
ized. Affinium Pharmaceuticals Inc. But beyond the computer stor-have shown that structural proteo-
is in the business to assess the age requirements, automated com-mics can contribute significantly to
three-dimensional structure of pro- puters, in the way of robots, are alsofunctional genomics. One consider-
teins that participate in bacterial or essential for sufficiently paced prog-able academic contribution was re-
viral infection. The characterized ress. Affinium has designed and de-ported in Nature Structural Biology
structure of a protein provides in- veloped its own automated high-in 2000. This article showed the sci-
sight into its function as well as a throughput, large-scale purificationentific muscle they put behind infor-
template for the synthesis of a system, called ProteoMax. Dependingmative proteomics with their ability
chemical inhibitor. on expression levels, ProteoMaxto characterize 20% of 424 non-
The infected world of antibiotic can purify between 20–150 mgs of
resistance will most likely be alle- protein in less than 24 hr. This cus-
viated by an antibiotic that was tom-made apparatus is fully auto-
“We can take an atomicdesigned by structure-guided re- mated, and the protein product
is 95% pure. For protein applica-search. Continuing to serendipi- walk around the molecule
tously acquire new antibiotics, as tion, Affinium has developed theand make a list of targets
has been done in previous decades, Gem crystallization system using an
based on druggability.”will only create short-term relief until industrial Cartesian robot from Ad-
ept Technology. The Gem is cus-resistance evolves. Structural biol- –John Mendlein, PhD,
ogy allows for more control over the tomized for versatile protein crys-CEO, Affinium Pharma-
mechanism of bacterial inhibition. tallization, and was designed to
ceuticals“We can take an atomic walk automatically prepare the crystal-
around the molecule and make a list lization screens from the stock so-
of targets based on druggability,” lutions as well as carry out pre-
membrane proteins from Methano-explains John Mendlein, PhD and programmed crystal optimization
bacterium thermoautotrophicum, anCEO of Affinium Pharmaceuticals. screens. The more difficult automa-
archeon which shares many se-This approach involves the crystalli- tion task is determining the optimi-
quence and functional features withzation and three-dimensional analy- zation strategy for each individual
eukaryotic proteins but is smallersis of bacterial and viral proteins. crystallization experiment, which
and more robust, and thus an excel-The specific structure information can number in the thousands. And,
lent model system for complex pro-provided by this analysis helps de- while there have been advances in
cesses. The goal of this large under-termine if the protein has accessible automated image capturing, there is
taking was to determine a sufficientand vulnerable sites, such that cog- no system in existence that can com-
number of three-dimensional struc-nate chemical compounds can be pletely replace human inspection.
tures necessary to define a “basicsynthesized with the hope that they Affinium, located in Toronto,
parts list” of protein folds [1].will inhibit the bacterial or viral tar- Canada, was founded in 2000 by Ed-
For Affinium, an ongoing goal be-get. Subsequent cocrystallization of wards, Arrowsmith, and Greenblatt
yond obtaining X-ray crystallo-the chemical inhibitor bound to the as Integrative Proteomics, Inc (IPI).
graphic data for various proteins isprotein can then reveal any re- After two years of intensive work au-
to find adequate methods for auto-maining sites to be masked or modi- tomating their setup and incor-
mating the process wherever possi-fied for enhanced potency. “If we poration of new management, IPI
ble. The laborious protocol for ob-see the (inhibitor-target complex) changed its name to Affinium Phar-
taining a protein structure involveswagging in solution, we may decide maceuticals, Inc., which they felt
purifying highly concentrated proteinto put a carboxylic acid on to make it more accurately reflected their stra-
(10 mg/ml), applying betweenmore water soluble,” says Mendlein. tegic focus of integrated, structure-
guided drug discovery.“You want active chemical matter 1,000–10,000 drops of the protein to
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Nicole L. Ballew is a freelance scienceWith the automation systems in pany with these particular Staph in-
writer based in Lebanon, NH (nballew@hand, Affinium’s primary focus has hibitors. Their competitors (albeit
hotmail.com).been in the area of anti-infectives. friendly) include SGX (Structural Ge-
nomix), Syrrx, Astex, and Quorex. TheIn the antiviral and antimicrobial re-
search realms, it has been noted that need for many types of antibiotics
is vast, and these companies coexistthe amount of structure data for viral
proteins far exceeds that available quite happily. As Mendlein explains,
“Nature’s a big place, and there arefor microbial proteins. Dr. Mendlein
explains that this discrepancy is a lot of important therapeutic pro-
teins. There are 900 kinases, and wecaused by two things: “The advent
of AIDS in the early 1980s,” which aren’t going to get them all and nei-
ther is one of our competitors.”created a big push for viral research,
and the fact that “cell-based assays In addition to their Staph inhibi-
tors, Affinium has an antiviral pro-are so easy in the antibacterial arena
that there was not much drive on the gram including structure studies on
the hepatitis C viral protein. Theystructure side.” Another contribut-
ing factor, according to Mendlein, also have programs focused on
high-resolution target structure per-was that in the 1970s the World
Health Organization claimed that in- taining to pharmaceutically or bio-
logically validated drug targets andfectious disease had been cured
and there was no need for new anti- a number of promising active small
molecules. Furthermore, Affiniumbiotics. This claim about antibiotics
was obviously incorrect, as resis- has over 200 internally generated
proprietary targets from infectioustance to current antibiotic drugs is
a definite and threatening problem. organisms that are in the early stages
of discovery, many of which haveUsing the approach whereby ac-
quisition of a bacterial (or viral) pro- high-resolution structural information.
Mendlein claims that the abilitytein structure is used as a template
to design chemical inhibitors, Affin- to triage targets based on the vol-
umes of acquired structural informa-ium has obtained intellectual prop-
erty around their high resolution tar- tion is crucial for efficient pursuit of
novel targets. He points out, “We aregets and novel chemical inhibitors
against Staphylococci. Thus far, they swimming in a sea of targets. We
can screen millions of compoundshave been able to show excellent
antibacterial activity against methi- virtually—that is a lot faster than
building an assay and retesting yourcillin-resistant Staphylococcus aureus
(MRSA), vancomycin-intermediate compounds, which literally could
take months.” In just three years, Af-and vancomycin-resistant Staphylo-
coccus aureus (VISA, VRSA), and finium, with its 55 employees, has
established the ability to determinecoagulase-negative Staphylococcus
(CoNS). Specifically, Affinium has protein structures in as little as
20–30 days and filed patents for overnovel chemical inhibitors against
these four types of Staph infections 400 targets and 16 small molecule
inhibitors in anti-infectives and otherthat have never been found in the
public domain, and are set to enter disease categories. With humble en-
thusiasm, Mendlein claims, “On theclinical trials at the end of 2004.
These chemical inhibitors target the ability to produce active targets and
determine their structures, we areFabI protein involved in the essential
fatty acid biosynthesis pathway in one of the top three companies in
bacteria. In addition to chemical in- the world.”
hibitors of the FabI protein in
S. aureus, Affinium has also syn- References
thesized molecules for the chemical
1. Christendat, D., Yee, A., Dharamsi, A.,inhibition of FabK in Streptococcus
Kluger, Y., Saychenko, A., Cort, J.R.,pneumoniae and FabI in Helico-
Booth, V., Mackereth, C.D., Saridakis,
bacter pylori. Mendlein claims that V., Ekiel, I., et al. (2000). Structural pro-
these synthetic antibiotic molecules teomics of an archaeon. Nat. Struct.
will be the first in the clinic from a Biol. 7, 903–909.
bacterial genomics target.
Chemistry & Biology invites yourAffinium is certainly not the only
comments on this topic. Pleaseresearch company focusing on
write to the editors at chembiol@structure-guided anti-infective re-
search. However, it is the only com- cell.com.
